Fully 16 of the corporate FCPA enforcement actions in 2016 were derived from China. Since 2012 well over 25 percent of all FCPA enforcements were derived from this single country. The Shearman & Sterling 2017 FCPA Digest opines why the reasons are varied, including, “(i) China’s size (both as a matter of geography and population); (ii) China’s role in the global economy; (iii) the similarity between bribery schemes arising out of China (i.e., gifts, travel, and entertainment); and (iv) the fact that many of the China-related bribery schemes involved the same industry (i.e., the healthcare and life science sectors).” These factors have no doubt led in part to the internal Chinese crackdown on domestic corruption and the bribery action against GSK in 2014.
